Drug Type Monoclonal antibody |
Synonyms Ocaratuzumab (USAN/INN), AME-133, AME-133V + [3] |
Target |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), CD20-directed cytolytic effects |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10482 | Ocaratuzumab | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Hodgkin Lymphoma | Phase 2 | US | 01 Jul 2006 | |
Follicular Lymphoma | Phase 2 | - | - | |
CD20 positive B-Cell Lymphoma | Phase 1 | US | 01 Jan 2015 | |
Rheumatoid Arthritis | Phase 1 | US | - |
Phase 1/2 | 50 | xijssfdlsd(xyyxbvqkan) = uddaczqmgf telpmkegjg (fyktsambmw ) View more | Positive | 01 Jan 2015 | |||
Not Applicable | - | ubqnavvfaq(jbspfdisql) = vymnpklebr feipogrpqz (pisuelaidv ) View more | - | 09 Nov 2012 | |||
sbvojbjnij(wwiianxuyh) = dhxldxaaaa uxfxotmvgg (glivjchzbp ) | |||||||
Not Applicable | 56 | rcidonkyhj(vjsbxfmfhl) = mcoxrlgpgg dimovvwqhi (qdprtqjzac ) View more | - | 20 May 2012 |